Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) (TA793)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2022
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2021
Belimumab for treating lupus nephritis (terminated appraisal) (TA806)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Obinutuzumab for treating serologically active extra-renal lupus [TSID12285]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 March 2026
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC